secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2023-10-05T23:59:59+00:00
Accession:  0001104659-23-107161
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron expects $100M pre-tax IPR&D charge in Q3 2023 from Alnylam milestone
------------------------------------------------------------------------------

- Acquired IPR&D charge of $100M pre-tax due to clinical milestone for ALN-APP Alzheimer's program.
- Charge expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.78 in Q3 2023.
- Milestone relates to collaboration with Alnylam Pharmaceuticals (ALNY) for early-onset Alzheimer's therapy.
- Results for Q3 not finalized; actual amounts may differ from preliminary estimates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465923107161/0001104659-23-107161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465923107161/tm2327767d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-107161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer